- Home
- LDTC vs GANX Comparison
LDTC vs GANX Comparison
Compare LDTC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- GANX
- Stock Information
- Founded
- LDTC 2007
- GANX 2017
- Country
- LDTC Canada
- GANX United States
- Employees
- LDTC N/A
- GANX N/A
- Industry
- LDTC Blank Checks
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- GANX Health Care
- Exchange
- LDTC Nasdaq
- GANX Nasdaq
- Market Cap
- LDTC 7.9M
- GANX 41.9M
- IPO Year
- LDTC N/A
- GANX 2021
- Fundamental
- Price
- LDTC $0.28
- GANX $2.73
- Analyst Decision
- LDTC Buy
- GANX Strong Buy
- Analyst Count
- LDTC 3
- GANX 4
- Target Price
- LDTC $1.00
- GANX $7.75
- AVG Volume (30 Days)
- LDTC 228.2K
- GANX 447.9K
- Earning Date
- LDTC 08-14-2024
- GANX 11-12-2024
- Dividend Yield
- LDTC N/A
- GANX N/A
- EPS Growth
- LDTC N/A
- GANX N/A
- EPS
- LDTC N/A
- GANX N/A
- Revenue
- LDTC $6,052,694.00
- GANX N/A
- Revenue This Year
- LDTC N/A
- GANX N/A
- Revenue Next Year
- LDTC $2.28
- GANX $300.03
- P/E Ratio
- LDTC N/A
- GANX N/A
- Revenue Growth
- LDTC 2.76
- GANX N/A
- 52 Week Low
- LDTC $0.24
- GANX $0.89
- 52 Week High
- LDTC $11.20
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- LDTC 41.42
- GANX 70.75
- Support Level
- LDTC $0.24
- GANX $2.45
- Resistance Level
- LDTC $0.29
- GANX $3.19
- Average True Range (ATR)
- LDTC 0.03
- GANX 0.29
- MACD
- LDTC 0.01
- GANX 0.06
- Stochastic Oscillator
- LDTC 77.92
- GANX 72.98
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.